Excess Mortality in Bipolar Disorders

Current Psychiatry Reports

Volumn 16, Issue 11, 2014, Pages

  Miller, Christopher ^a,b   Bauer, Mark S ^a,b  

^a VA BOSTON HEALTHCARE SYSTEM   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Bipolar; Cardiovascular; Mortality; Suicide

Indexed keywords

ANTIDEPRESSANT AGENT; LITHIUM; OLANZAPINE; QUETIAPINE; RISPERIDONE; VALPROIC ACID;

ACUTE HEART INFARCTION; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CEREBROVASCULAR DISEASE; COGNITIVE THERAPY; DISEASE SEVERITY; ELECTROCONVULSIVE THERAPY; EVIDENCE BASED MEDICINE; FOLLOW UP; HEART ARREST; HUMAN; INSULIN RELEASE; INTERPERSONAL COMMUNICATION; ISCHEMIC HEART DISEASE; MORTALITY; OBSERVATIONAL STUDY; OPEN STUDY; PHYSICAL CAPACITY; PRESCRIPTION; PSYCHOEDUCATION; PSYCHOSOCIAL CARE; PSYCHOSOMATIC DISORDER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SCHIZOPHRENIA; SELF CARE; SUICIDAL IDEATION; WEIGHT GAIN; BIPOLAR DISORDER; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; STATISTICS AND NUMERICAL DATA; SUICIDE;

BIPOLAR DISORDER; CARDIOVASCULAR DISEASES; HUMANS; SUICIDE;

EID: 84920261738     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-014-0499-z     Document Type: Review

References (75)

1. Andlin-Sobocki P, Wittchen HU. Cost of affective disorders in Europe. Eur J Neurol. 2005;12 Suppl 1:34–8.
2. Baldessarini RJ, Tondo L. Suicide risk and treatments for patients with bipolar disorder. JAMA. 2003;290:1517–9.
3. Peele PB, Xu Y, Kupfer DJ. Insurance expenditures on bipolar disorder: clinical and parity implications. Am J Psychiatr. 2003;160:1286–90.
4. Weiner M, Warren L, Fiedorowicz JG. Cardiovascular morbidity and mortality in bipolar disorder. Ann Clin Psychiatry. 2011;23:40–7.
5. Chang CK, Hayes RD, Broadbent M, et al. All-cause mortality among people with serious mental illness (SMI), substance use disorders, and depressive disorders in southeast London: a cohort study. BMC Psychiatry. 2010;10:77.
6. Laursen TM, Wahlbeck K, Hallgren J, et al. Life expectancy and death by diseases of the circulatory system in patients with bipolar disorder or schizophrenia in the Nordic countries. PLoS One. 2013;8:e67133.
7. Hoang U, Stewart R, Goldacre MJ. Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999–2006. BMJ Br Med J. 2011;343:d5422.
8. Mitchell PB, Hadzi-Pavlovic D. Lithium treatment for bipolar disorder. Bull World Health Organ. 2000;78:515–7.
9. McElroy SL, Keck Jr PE, Pope Jr HG, et al. Valproate in the treatment of bipolar disorder: literature review and clinical guidelines. J Clin Psychopharmacol. 1992;12:42S–52.
10. Hirschfeld RMA, Kasper S. A review of the evidence for carbamazepine and oxcarbazepine in the treatment of bipolar disorder. Int J Neuropsychopharmacol. 2004;7:507–22.
11. Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry. 2007;64:442–55.
12. Cruz N, Sanchez-Moreno J, Torres F, et al. Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. Int J Neuropsychopharmacol. 2010;13:5–14.
13. De Fruyt J, Deschepper E, Audenaert K, et al. Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis. J Psychopharmacol. 2012;26:603–17.
14. Smith LA, Cornelius V, Warnock A, et al. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disord. 2007;9:394–412.
15. Perry A, Tarrier N, Morriss R, et al. Randomised controlled trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment. BMJ Br Med J. 1999;318:149–53.
16. Colom F, Vieta E, Sanchez-Moreno J, et al. Group psychoeducation for stabilised bipolar disorders: 5-year outcome of a randomised clinical trial. Br J Psychiatr. 2009;194:260–5.
17. Bauer MS, Kilbourne AM, Greenwald DE, et al. Overcoming bipolar disorder. Oakland: New Harbinger Publications, Inc; 2008.
18. Miklowitz DJ, George EL, Richards JA, et al. A randomized study of family-focused psychoeducation and pharmacotherapy in the outpatient management of bipolar disorder. Arch Gen Psychiatry. 2003;60:904–12.
19. Frank E, Kupfer DJ, Thase ME, et al. Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch Gen Psychiatry. 2005;62:996–1004.
20. Harris EC, Barraclough B. Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatr. 1997;170:205–28.
21. Tondo L, Isacsson G, Baldessarini R. Suicidal behaviour in bipolar disorder: risk and prevention. CNS Drugs. 2003;17:491–511.
22. Pompili M, Gonda X, Serafini G, et al. Epidemiology of suicide in bipolar disorders: a systematic review of the literature. Bipolar Disord. 2013;15:457–90.
23. Antypa N, Antonioli M, Serretti A. Clinical, psychological and environmental predictors of prospective suicide events in patients with bipolar disorder. J Psychiatr Res. 2013;47:1800–8.
24. Fossati A, Maffei C, Bagnato M, et al. Brief communication: criterion validity of the personality diagnostic questionnaire-4+ (PDQ-4+) in a mixed psychiatric sample. J Pers Disord. 1998;12:172–8.
25. Yoon YH, Chen CM, Yi HY, et al. Effect of comorbid alcohol and drug use disorders on premature death among unipolar and bipolar disorder decedents in the United States, 1999 to 2006. Compr Psychiatry. 2011;52:453–64.
26. Gonda X, Pompili M, Serafini G, et al. Suicidal behavior in bipolar disorder: epidemiology, characteristics and major risk factors. J Affect Disord. 2012;143:16–26.
27. Fiedorowicz JG, Leon AC, Keller MB, et al. Do risk factors for suicidal behavior differ by affective disorder polarity? Psychol Med. 2009;39:763–71.
28. Rihmer A, Gonda X, Balazs J, et al. The importance of depressive mixed states in suicidal behaviour. Neuropsychopharmacol Hung. 2008;10:45–9.
29. Balazs J, Benazzi F, Rihmer Z, et al. The close link between suicide attempts and mixed (bipolar) depression: implications for suicide prevention. J Affect Disord. 2006;91:133–8.
30. Valtonen HM, Suominen K, Haukka J, et al. Differences in incidence of suicide attempts during phases of bipolar I and II disorders. Bipolar Disord. 2008;10:588–96.
31. Valtonen HM, Suominen K, Mantere O, et al. Suicidal behaviour during different phases of bipolar disorder. J Affect Disord. 2007;97:101–7.
32. Holma KM, Haukka J, Suominen K, et al. Differences in incidence of suicide attempts between bipolar I and II disorders and major depressive disorder. Bipolar Disord. 2014.
33. Undurraga J, Baldessarini RJ, Valenti M, et al. Suicidal risk factors in bipolar I and II disorder patients. J Clin Psychiatr. 2012;73:778–82.
34. Tidemalm D, Haglund A, Karanti A, et al. Attempted suicide in bipolar disorder: risk factors in a cohort of 6086 patients. PLoS One. 2014;9:e94097.
35. Gonda X, Fountoulakis KN, Kaprinis G, et al. Prediction and prevention of suicide in patients with unipolar depression and anxiety. Ann Gen Psychiatr. 2007;6:23.
36. Barry CL, Busch SH. News coverage of FDA warnings on pediatric antidepressant use and suicidality. Pediatrics. 2010;125:88–95.
37. Lu CY, Zhang F, Lakoma MD, et al. Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study. BMJ Br Med J. 2014;348:g3596.
38. Leon AC, Fiedorowicz JG, Solomon DA, et al. Risk of suicidal behavior with antidepressants in bipolar and unipolar disorders. J Clin Psychiatr. 2014;75:720–7.
39. Dennehy EB, Marangell LB, Allen MH, et al. Suicide and suicide attempts in the systematic treatment enhancement program for bipolar disorder (STEP-BD). J Affect Disord. 2011;133:423–7.
40. Pacchiarotti I, Bond DJ, Baldessarini RJ, et al. The international society for bipolar disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatr. 2013;170:1249–62.
41. Mitchell PB, Frankland A, Hadzi-Pavlovic D, et al. Comparison of depressive episodes in bipolar disorder and in major depressive disorder within bipolar disorder pedigrees. Br J Psychiatr. 2011;199:303–9.
42. Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003;60:261–9.
43. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59:530–7.
44. Tondo L, Hennen J, Baldessarini RJ. Lower suicide risk with long-term lithium treatment in major affective illness: a meta-analysis. Acta Psychiatr Scand. 2001;104:163–72.
45. Ahrens B, Müller-Oerlinghausen B. Does lithium exert an independent antisuicidal effect? Pharmacopsychiatry. 2001;34(4):132–6.
46. Cipriani A, Hawton K, Stockton S, et al. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ. 2013. doi:10.1136/bmj.f3646.
47. Lauterbach E, Felber W, Müller‐Oerlinghausen B, et al. Adjunctive lithium treatment in the prevention of suicidal behaviour in depressive disorders: a randomised, placebo‐controlled, 1‐year trial. Acta Psychiatr Scand. 2008;118:469–79.
48. Oquendo MA, Galfalvy HC, Currier D, et al. Treatment of suicide attempters with bipolar disorder: a randomized clinical trial comparing lithium and valproate in the prevention of suicidal behavior. Am J Psychiatr. 2011;168:1050–6.
49. Nierenberg AA, Friedman ES, Bowden CL, et al. Lithium treatment moderate-dose use study (LiTMUS) for bipolar disorder: a randomized comparative effectiveness trial of optimized personalized treatment with and without lithium. Am J Psychiatr. 2013;170:102–10.
50. Geddes JR, Goodwin GM, Rendell J, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet. 2010;375:385–95.
51. Katz IR, Liang M, Morgenstern NC. Lithium for suicidal behavior in mood disorders (Li+). Clinicaltrials.gov: United States National Institutes of Health, 2014.
52. Pagnin D, de Queiroz V, Pini S, et al. Efficacy of ECT in depression: a meta-analytic review. J ECT. 2004;20:13–20.
53. Mukherjee S, Sackeim HA, Schnur DB. Electroconvulsive therapy of acute manic episodes: a review of 50 years’ experience. Am J Psychiatr. 1994;151:169–76.
54. Loo C, Katalinic N, Mitchell PB, et al. Physical treatments for bipolar disorder: a review of electroconvulsive therapy, stereotactic surgery and other brain stimulation techniques. J Affect Disord. 2011;132:1–13.
55. Versiani M, Cheniaux E, Landeira-Fernandez J. Efficacy and safety of electroconvulsive therapy in the treatment of bipolar disorder: a systematic review. J ECT. 2011;27:153–64.
56. Minnai GP, Salis PG, Oppo R, et al. Effectiveness of maintenance electroconvulsive therapy in rapid-cycling bipolar disorder. J ECT. 2011;27:123–6.
57. Cuijpers P, de Beurs DP, van Spijker BA, et al. The effects of psychotherapy for adult depression on suicidality and hopelessness: a systematic review and meta-analysis. J Affect Disord. 2013;144:183–90.
58. Gonzalez Isasi A, Echeburua E, Liminana JM, et al. Psychoeducation and cognitive-behavioral therapy for patients with refractory bipolar disorder: a 5-year controlled clinical trial. Eur Psychiatry. 2014;29:134–41.
59. Costa RT, Cheniaux E, Rosaes PA, et al. The effectiveness of cognitive behavioral group therapy in treating bipolar disorder: a randomized controlled study. Rev Bras Psiquiatr. 2011;33:144–9.
60. Bouwkamp CG, de Kruiff ME, van Troost TM, et al. Interpersonal and social rhythm group therapy for patients with bipolar disorder. Int J Group Psychother. 2013;63:97–115.
61. Derby IM. Manic-depressive “exhaustion” deaths. Psychiatr Q. 1933;7:436–49.
62. Mendis S, Puska P, Norrving B. Global atlas on cardiovascular disease prevention and control. World Health Organization; 2011.
63. Laursen TM, Munk-Olsen T, Gasse C. Chronic somatic comorbidity and excess mortality due to natural causes in persons with schizophrenia or bipolar affective disorder. PLoS One. 2011;6:e24597.
64. Westman J, Hallgren J, Wahlbeck K, et al. Cardiovascular mortality in bipolar disorder: a population-based cohort study in Sweden. BMJ Open. 2013. doi:10.1136/bmjopen-2012-002373.
65. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31–41.
66. Reist C, Mintz J, Albers LJ, et al. Second-generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia: an observational pharmacoepidemiology study from 1988 to 2002. J Clin Psychopharmacol. 2007;27:46–51.
67. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19 Suppl 1:1–93.
68. Guo JJ, Keck Jr PE, Corey-Lisle PK, et al. Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: a retrospective, population-based, case–control study. J Clin Psychiatr. 2006;67:1055–61.
69. Ngai YF, Sabatini P, Nguyen D, et al. Quetiapine treatment in youth is associated with decreased insulin secretion. J Clin Psychopharmacol. 2014;34:359–64.
70. Chen CH, Lin TY, Chen TT, et al. A prospective study of glucose homeostasis in quetiapine-treated schizophrenic patients by using the intravenous glucose tolerance test. Progr Neuro Psychopharmacol Biol Psychiatr. 2011;35:965–9.
71. Laursen TM, Mortensen PB, MacCabe JH, et al. Cardiovascular drug use and mortality in patients with schizophrenia or bipolar disorder: a Danish population-based study. Psychol Med. 2014;44:1625–37.
72. Kilbourne AM, Lai Z, Bowersox N, et al. Does colocated care improve access to cardiometabolic screening for patients with serious mental illness? Gen Hosp Psychiatry. 2011;33:634–6.
73. Kilbourne AM, Goodrich DE, Lai Z, et al. Randomized controlled trial to assess reduction of cardiovascular disease risk in patients with bipolar disorder: the self-management addressing heart risk trial (SMAHRT). J Clin Psychiatr. 2013;74:e655–62.
74. Goodrich DE, Kilbourne AM, Lai Z, et al. Design and rationale of a randomized controlled trial to reduce cardiovascular disease risk for patients with bipolar disorder. Contemp Clin Trials. 2012;33:666–78.
75. Davis CL, Kilbourne AM, Blow FC, et al. Reduced mortality among Department of Veterans Affairs patients with schizophrenia or bipolar disorder lost to follow-up and engaged in active outreach to return for care. Am J Public Health. 2012;102 Suppl 1:S74–9.